These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17355491)

  • 21. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen.
    Anderson FD; Hait H; Hsiu J; Thompson-Graves AL; Wilborn WH; Williams RF
    Contraception; 2005 Jan; 71(1):55-9. PubMed ID: 15639074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.
    Anderson FD; Feldman R; Reape KZ
    Contraception; 2008 Feb; 77(2):91-6. PubMed ID: 18226671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
    Anderson FD; Gibbons W; Portman D
    Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval.
    Willis SA; Kuehl TJ; Spiekerman AM; Sulak PJ
    Contraception; 2006 Aug; 74(2):100-3. PubMed ID: 16860046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
    Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
    Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.
    Silberstein SD; Cady RK; Sheftell FD; Almas M; Parsons B; Albert KS
    Headache; 2007 May; 47(5):673-82. PubMed ID: 17501848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MIDAS and HIT-6 French translation: reliability and correlation between tests.
    Magnoux E; Freeman MA; Zlotnik G
    Cephalalgia; 2008 Jan; 28(1):26-34. PubMed ID: 17970768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
    Klipping C; Duijkers I; Trummer D; Marr J
    Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
    Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
    Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive/tertiary care for headache: a 6-month outcome study.
    Saper JR; Lake AE; Madden SF; Kreeger C
    Headache; 1999 Apr; 39(4):249-63. PubMed ID: 15613222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Women's issues of migraine in tertiary care.
    Kelman L
    Headache; 2004 Jan; 44(1):2-7. PubMed ID: 14979877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive.
    Reape KZ; DiLiberti CE; Hendy CH; Volpe EJ
    Contraception; 2008 Jan; 77(1):34-9. PubMed ID: 18082664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.
    Sulak PJ; Cressman BE; Waldrop E; Holleman S; Kuehl TJ
    Obstet Gynecol; 1997 Feb; 89(2):179-83. PubMed ID: 9015017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
    Lizogub VG; Riley DS; Heger M
    Explore (NY); 2007; 3(6):573-84. PubMed ID: 18005909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.